FDA s Accelerated Pathways Are the New Normal

The FDA s Accelerated Approval, Breakthrough Therapy Designation, Fast Track, Orphan Drug status, and Qualified Infectious Disease Product pathways facilitate faster development and approval of NDAs addressing unmet needs. According to the FDA s annual report, two-thirds of novel drugs approvedOriginal Article